NM_014363.6:c.11032C>G

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_014363.6(SACS):​c.11032C>G​(p.Pro3678Ala) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0283 in 1,613,774 control chromosomes in the GnomAD database, including 1,131 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.027 ( 105 hom., cov: 33)
Exomes 𝑓: 0.028 ( 1026 hom. )

Consequence

SACS
NM_014363.6 missense

Scores

3
5
9

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:12

Conservation

PhyloP100: 10.0

Publications

13 publications found
Variant links:
Genes affected
SACS (HGNC:10519): (sacsin molecular chaperone) This gene encodes the sacsin protein, which includes a UbL domain at the N-terminus, a DnaJ domain, and a HEPN domain at the C-terminus. The gene is highly expressed in the central nervous system, also found in skin, skeletal muscles and at low levels in the pancreas. This gene includes a very large exon spanning more than 12.8 kb. Mutations in this gene result in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), a neurodegenerative disorder characterized by early-onset cerebellar ataxia with spasticity and peripheral neuropathy. The authors of a publication on the effects of siRNA-mediated sacsin knockdown concluded that sacsin protects against mutant ataxin-1 and suggest that "the large multi-domain sacsin protein is able to recruit Hsp70 chaperone action and has the potential to regulate the effects of other ataxia proteins" (Parfitt et al., PubMed: 19208651). A pseudogene associated with this gene is located on chromosome 11. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2013]
SACS Gene-Disease associations (from GenCC):
  • Charlevoix-Saguenay spastic ataxia
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, G2P, Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), Myriad Women’s Health

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.002728641).
BP6
Variant 13-23332844-G-C is Benign according to our data. Variant chr13-23332844-G-C is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 260391.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.108 is higher than 0.05.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_014363.6. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
SACS
NM_014363.6
MANE Select
c.11032C>Gp.Pro3678Ala
missense
Exon 10 of 10NP_055178.3
SACS
NM_001437336.1
c.11059C>Gp.Pro3687Ala
missense
Exon 11 of 11NP_001424265.1
SACS
NM_001278055.2
c.10591C>Gp.Pro3531Ala
missense
Exon 8 of 8NP_001264984.1

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
SACS
ENST00000382292.9
TSL:5 MANE Select
c.11032C>Gp.Pro3678Ala
missense
Exon 10 of 10ENSP00000371729.3
SACS
ENST00000455470.6
TSL:1
c.2432-3360C>G
intron
N/AENSP00000406565.2
SACS
ENST00000682944.1
c.11059C>Gp.Pro3687Ala
missense
Exon 11 of 11ENSP00000507173.1

Frequencies

GnomAD3 genomes
AF:
0.0266
AC:
4051
AN:
152198
Hom.:
106
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00403
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0296
Gnomad ASJ
AF:
0.00806
Gnomad EAS
AF:
0.116
Gnomad SAS
AF:
0.0577
Gnomad FIN
AF:
0.0904
Gnomad MID
AF:
0.00633
Gnomad NFE
AF:
0.0223
Gnomad OTH
AF:
0.0220
GnomAD2 exomes
AF:
0.0405
AC:
10148
AN:
250504
AF XY:
0.0404
show subpopulations
Gnomad AFR exome
AF:
0.00370
Gnomad AMR exome
AF:
0.0484
Gnomad ASJ exome
AF:
0.00964
Gnomad EAS exome
AF:
0.104
Gnomad FIN exome
AF:
0.0860
Gnomad NFE exome
AF:
0.0227
Gnomad OTH exome
AF:
0.0306
GnomAD4 exome
AF:
0.0285
AC:
41590
AN:
1461458
Hom.:
1026
Cov.:
35
AF XY:
0.0292
AC XY:
21266
AN XY:
727066
show subpopulations
African (AFR)
AF:
0.00311
AC:
104
AN:
33470
American (AMR)
AF:
0.0450
AC:
2013
AN:
44722
Ashkenazi Jewish (ASJ)
AF:
0.00861
AC:
225
AN:
26128
East Asian (EAS)
AF:
0.125
AC:
4975
AN:
39690
South Asian (SAS)
AF:
0.0576
AC:
4966
AN:
86248
European-Finnish (FIN)
AF:
0.0848
AC:
4509
AN:
53146
Middle Eastern (MID)
AF:
0.0151
AC:
87
AN:
5768
European-Non Finnish (NFE)
AF:
0.0206
AC:
22919
AN:
1111894
Other (OTH)
AF:
0.0297
AC:
1792
AN:
60392
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.484
Heterozygous variant carriers
0
2551
5102
7653
10204
12755
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
926
1852
2778
3704
4630
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0266
AC:
4049
AN:
152316
Hom.:
105
Cov.:
33
AF XY:
0.0303
AC XY:
2259
AN XY:
74492
show subpopulations
African (AFR)
AF:
0.00402
AC:
167
AN:
41588
American (AMR)
AF:
0.0295
AC:
452
AN:
15300
Ashkenazi Jewish (ASJ)
AF:
0.00806
AC:
28
AN:
3472
East Asian (EAS)
AF:
0.116
AC:
599
AN:
5182
South Asian (SAS)
AF:
0.0579
AC:
280
AN:
4832
European-Finnish (FIN)
AF:
0.0904
AC:
959
AN:
10608
Middle Eastern (MID)
AF:
0.00680
AC:
2
AN:
294
European-Non Finnish (NFE)
AF:
0.0223
AC:
1516
AN:
68016
Other (OTH)
AF:
0.0218
AC:
46
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
210
420
631
841
1051
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
54
108
162
216
270
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0241
Hom.:
36
Bravo
AF:
0.0215
TwinsUK
AF:
0.0197
AC:
73
ALSPAC
AF:
0.0195
AC:
75
ESP6500AA
AF:
0.00477
AC:
21
ESP6500EA
AF:
0.0229
AC:
197
ExAC
AF:
0.0396
AC:
4807
Asia WGS
AF:
0.0660
AC:
228
AN:
3478
EpiCase
AF:
0.0196
EpiControl
AF:
0.0196

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:12
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:4
Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

Sep 13, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Feb 22, 2016
Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

not specified Benign:3
Dec 12, 2023
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

Charlevoix-Saguenay spastic ataxia Benign:3
Jul 01, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Sep 16, 2020
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

Jun 14, 2016
Illumina Laboratory Services, Illumina
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Spastic paraplegia Benign:1
Feb 02, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Hereditary spastic paraplegia Benign:1
Aug 30, 2021
Genome Diagnostics Laboratory, The Hospital for Sick Children
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.22
BayesDel_addAF
Benign
-0.32
T
BayesDel_noAF
Benign
-0.12
CADD
Uncertain
25
DANN
Uncertain
1.0
DEOGEN2
Benign
0.20
T
Eigen
Uncertain
0.67
Eigen_PC
Pathogenic
0.72
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Uncertain
0.92
D
MetaRNN
Benign
0.0027
T
MetaSVM
Benign
-0.60
T
MutationAssessor
Benign
1.6
L
PhyloP100
10
PrimateAI
Uncertain
0.76
T
PROVEAN
Benign
-0.81
N
REVEL
Uncertain
0.37
Sift
Benign
0.033
D
Sift4G
Pathogenic
0.0
D
Polyphen
1.0
D
Vest4
0.59
ClinPred
0.039
T
GERP RS
5.8
Varity_R
0.094
gMVP
0.63
Mutation Taster
=88/12
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs17078601; hg19: chr13-23906983; COSMIC: COSV66536684; API